Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening

ZHAN Na; XU Wei; ZENG Zhi; DONG Liling

doi:10.3971/j.issn.1000-8578.2022.22.0060

Cancer Research on Prevention and Treatment > 2022 > 49(9): 908-912. > DOI: 10.3971/j.issn.1000-8578.2022.22.0060

ZHAN Na, XU Wei, ZENG Zhi, DONG Liling. Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 908-912. DOI: 10.3971/j.issn.1000-8578.2022.22.0060

Citation:

PDF (10159 KB)

Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening

ZHAN Na^{1, 2},
XU Wei^2, ,,
ZENG Zhi^{1, 2},
DONG Liling³

1.
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
2.
Medical Examination Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
3.
Medical Examination Center, Union Jiangnan Hospital, Huazhong University of Science and Technology, Wuhan 430200, China

Funding:

Dr. Chinese Health Management Science Research Fund 2021HX0019

More Information

Corresponding author:
XU Wei, E-mail: 1535065582@qq.com
Received Date: January 17, 2022
Revised Date: May 23, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the application value of serum auto-antibody detection combined with low-dose spiral computed tomography (LDCT) in early lung cancer screening.
Methods
From 12568 medical examination crowd (7453 males and 5115 females), 1324 people with high-risk cases of lung cancer in our medical examination center were divided randomly into three groups (LDCT, serum auto-antibody, and serum auto-antibody combined with LDCT groups). All people in this research were screened by chest X-ray. Follow-up was conducted for one year, and the positive screening and diagnosis rates of early lung cancer screening were compared between these groups of high-risk people with lung cancer.
Results
The positive screening and diagnostic rates of high-risk lung cancer in the serum auto-antibody combined with LDCT group was significantly higher those that in other two groups (P < 0.001). The specificity and sensitivity of serum auto-antibody combined with LDCT group were 89.1% and 88.4%, respectively; the area under the ROC curve was 0.863.
Conclusion
Serum auto-antibody detection combined with low-dose spiral CT can significantly improve the positive screening rate of lung cancer in high-risk populations, providing a strong theoretical support for lung cancer screening pathway.
- Serum autoantibody detection,
- Low-dose spiral CT,
- Early stage lung cancer,
- High-risk population

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (22)

References

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[2]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
[3]	Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51. doi: 10.1016/j.jtho.2015.09.009
[4]	National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409. doi: 10.1056/NEJMoa1102873
[5]	Tang ZM, Ling ZG, Wang CM, et al. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(7): e182117.
[6]	杨景伟, 尹德军, 刘玉霞, 等. 血清自身抗体检测联合低剂量螺旋CT在早期肺癌筛查中的临床价值[J]. 系统医学, 2019, 4(17): 10-13. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX201917004.htm Yang JW, Yin DJ, Liu YX, et al. Clinical value of serum autoantibody detection combined with low-dose spiral CT in early lung cancer screening[J]. Xi Tong Yi Xue, 2019, 4(17): 10-13. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX201917004.htm
[7]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108
[8]	Wang Q, Wang Q, Wang SF, et al. Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis[J]. Curr Oncol, 2017, 24(4): e269-e276. doi: 10.3747/co.24.3561
[9]	Petpiroon N, Bhummaphan N, Tungsukruthai S, et al. Chrysotobibenzyl inhibition of lung cancer cell migration through Caveolin-1-dependent mediation of the integrin switch and the sensitization of lung cancer cells to cisplatin-mediated apoptosis[J]. Phytomedicine, 2019, 58: 152888. doi: 10.1016/j.phymed.2019.152888
[10]	Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening[J]. Eur Radiol, 2015, 25(9): 2519-2531. doi: 10.1007/s00330-015-3697-0
[11]	Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017, 377(9): 849-861. doi: 10.1056/NEJMra1703413
[12]	Guo W, Hu M, Wu J, et al. Gprc5a depletion enhances the risk of smoking-induced lung tumorigenesis and mortality[J]. Biomed Pharmacother, 2019, 114: 108791. doi: 10.1016/j.biopha.2019.108791
[13]	Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer[J]. Lung Cancer, 2014, 86(1): 78-84. doi: 10.1016/j.lungcan.2014.07.020
[14]	Ullah MF, Aatif M. The footprints of cancer development: Cancer biomarkers[J]. Cancer Treat Rev, 2009, 35(3): 193-200. doi: 10.1016/j.ctrv.2008.10.004
[15]	Jett J, Healey G, Macdonald I, et al. Determination of the Detection Lead Time for Autoantibody Biomarkers in Early Stage Lung Cancer Using the UKCTOCS Cohort[J]. J Thorac Oncol, 2017, 122(11): S2170.
[16]	Brims F, McWilliams A, Fong K. Lung cancer screening in Australia: progress or procrastination?[J]. Med J Aust, 2016, 204(1): 4-5. doi: 10.5694/mja15.01109
[17]	Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera[J]. J Clin Oncol, 2008, 26(31): 5060-5066. doi: 10.1200/JCO.2008.16.2388
[18]	Leavitt J, Pangilinan J. 2019 World conference of lung cancer round-up[J]. Oncology (Williston Park), 2019, 33(11): 687519.
[19]	中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志, 2021, 43(6): 591-621. doi: 10.3760/cma.j.cn112152-20210207-00118 Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2021 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2021, 43(6): 591-621. doi: 10.3760/cma.j.cn112152-20210207-00118
[20]	Ren S, Zhang S, Jiang T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population[J]. Oncoimmunology, 2018, 7(2): e1384108. doi: 10.1080/2162402X.2017.1384108
[21]	Massion PP, Healey GF, Peek LJ, et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer[J]. J Thorac Oncol, 2017, 12(3): 578-584. doi: 10.1016/j.jtho.2016.08.143
[22]	Du Q, Yu R, Wang H, et al. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer[J]. Clin Respir J, 2018, 12(6): 2020-2028. doi: 10.1111/crj.12769

[1]	LI Shijun, QI Junyuan. Treatment of High-risk Myelodysplastic Syndrome[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 996-1002. DOI: 10.3971/j.issn.1000-8578.2020.20.0412
[2]	WANG Lidong, HAN Wenli, SONG Xin, ZHAO Xueke, HU Shoujia, WANG Panpan, YANG Miaomiao. Understanding and Thinking About Key Scientific Issues in Esophageal Cancer Research[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 83-89. DOI: 10.3971/j.issn.1000-8578.2020.19.0964
[3]	ZHONG Haojie, LUO Wenhui, LIU Yongjia, LIN Da, XUE Lanfeng, CHEN Yu. Progress in Follow-up of High-risk Factors After Endoscopic Resection of Colorectal Tumors[J]. Cancer Research on Prevention and Treatment, 2019, 46(4): 371-375. DOI: 10.3971/j.issn.1000-8578.2019.18.1406
[4]	ZHANG Yachen, LIANG Di, JIN Jing, LI Daojuan, LIU Congmin, GAO Zhaoyu, HE Yutong. Research Progress on Risk Factors for Lung Cancer in Nonsmokers[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 501-505. DOI: 10.3971/j.issn.1000-8578.2017.16.1627
[5]	CAI Yuqun, WAN Huiqing, GUO Qiaozhen, LI Wei, ZHOU Jianhong. Value of High-risk Human Papilloma Virus Infection in Preliminary Screening of Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(06): 610-613. DOI: 10.3971/j.issn.1000-8578.2015.06.017
[6]	WU Xin-yin, HUANG Min-zhu, LI Hong-bo, FENG Xiao-dong, ZENG Zheng-yu. Analysis of High-risk HPV Cervical Infection and Its Dose-effect Relationship between hrHPV Virus Load and Cervical Lesion[J]. Cancer Research on Prevention and Treatment, 2009, 36(02): 158-161. DOI: 10.3971/j.issn.1000-8578.2009.02.022
[7]	ZHU Zhao-yang, ZHANG Zhi-feng, LI Chang-feng, WAN Jun, DUAN Ji-jun. Analysis on Risk Factors of Lung Cancer in the City Zone of Wuhan[J]. Cancer Research on Prevention and Treatment, 2007, 34(08): 633-635. DOI: 10.3971/j.issn.1000-8578.2351
[8]	ZHENG ZHi-jian, HUANG Guo-dong, HE Yan-mei, et al, . Surveillance of high risk pedigree for nasopharyngeal carcinoma in Meizhou[J]. Cancer Research on Prevention and Treatment, 2002, 29(06): 498-499. DOI: 10.3971/j.issn.1000-8578.163
[9]	Liu XY, . Evaluation of Optimized Screening Protocol for Colorectal Cancer among a High-incidence Population[J]. Cancer Research on Prevention and Treatment, 1997, 24(4): 197-200.
[10]	Zho Zhenying, . Comparative study on flow cytometry,hlstopathology and endoscopy in tumor high-risk regional people[J]. Cancer Research on Prevention and Treatment, 1994, 21(3): 154-156.

Cited By

Cited by

Periodical cited type(9)

1.	成俊，徐雪峰，李伟. D-CBCT在肺癌容积旋转调强计划精准治疗中的临床应用. 中国CT和MRI杂志. 2024(04): 35-37 .
2.	蒋浩，曹新超，吴桐，郭志斌. 低剂量CT联合外周血循环肿瘤细胞在肺癌早期诊断中的价值研究. 中国CT和MRI杂志. 2024(06): 57-60 .
3.	王晶，翟成凯. 肿瘤自身抗体及CT人工智能在NSCLC早期诊断中的应用研究进展. 解放军医学杂志. 2024(07): 848-854 .
4.	李雪娇. 多排螺旋CT低剂量胸部扫描在肺癌早期筛查中的应用价值分析. 医药前沿. 2024(15): 79-81 .
5.	易梅玲，易芳玲. 双层探测器光谱CT智能剂量调控技术在低剂量胸部体检中的应用价值. 中国医疗器械信息. 2024(22): 8-10+81 .
6.	杏子，彭源. 低剂量CT在肺癌筛查中的价值. 中国防痨杂志. 2024(S2): 234-236 .
7.	陈蔚，蒋伟. 低剂量螺旋CT扫描用于肺癌筛查及鉴别的效果评估. 深圳中西医结合杂志. 2023(01): 71-73 .
8.	慕珂珂，肖凌云，董炎红. 早期肺癌患者血清和胸腔积液中CYFRA211、NSE及SCC水平变化及意义. 中国实用医刊. 2023(09): 34-37 .
9.	陈彪. 低剂量螺旋CT联合血清肿瘤标志物在肺癌诊断中的临床应用价值. 影像研究与医学应用. 2023(22): 24-26 .

Other cited types(1)

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article views (1143) PDF downloads (150) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening